We are live on ! Find out more
ERNA icon

Ernexa Therapeutics

10 hedge funds and large institutions have $750K invested in Ernexa Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 10 → 10 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.14% less ownership

Funds ownership: 6.47% → 6.32% (-0.14%)

9% less capital inflows, than outflows

Capital inflows: $67.6K | Capital outflows: $74.3K

Holders
10
Holders Change
–
Holders Change %
0%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ERNA Hedge Fund Activity: Q2 2023 in Review

10 of the 6,391 institutional investors tracked by Wall St. Rank reported a position in Ernexa Therapeutics (ERNA) for Q2 2023, worth a combined $750K — down 34% from $1.14M a quarter earlier.

Fund positioning in ERNA was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 2 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $30.2K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $44K sold.

  • 10 institutional investors held Ernexa Therapeutics (ERNA) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $750K of Ernexa Therapeutics stock for Q2 2023, down 34% quarter-over-quarter.
  • 2 funds opened new Ernexa Therapeutics positions in Q2 2023 and 2 closed out, a net change of 0 holders.
  • The largest Ernexa Therapeutics buyer in Q2 2023 was Goldman Sachs, an estimated $30.2K added.
  • The largest Ernexa Therapeutics seller in Q2 2023 was Renaissance Technologies, an estimated $44K sold.

Based on aggregated 13F filings for Q2 2023.